On March 25th, Daxing District Government, AstraZeneca, Minhai Biological and other companies signed a strategic cooperation memorandum in Daxing, Beijing, to jointly explore the mode of cooperation in the field of vaccines, and help China's vaccine innovation products to cooperate and develop at home and abroad.

Daxing District's life and health industry ecosystem has been continuously improved, creating a favorable business environment that attracts foreign investment and strengthens the confidence of global outstanding enterprises in long-term development in Beijing. The strategic cooperation between AstraZeneca and Minhai Biotechnology will further expand the circle of friends and influence of Daxing District's world-class vaccine industry cluster, and will become a substantive measure for Daxing District to implement the "Action Plan for Attracting and Utilizing Foreign Investments with Greater Efforts by Solidly Pushing Forward the Opening Up of the Country to the Outside World at a High Level".

This time in Beijing Daxing to jointly explore the cooperation mode in the field of vaccines, Daxing District and AstraZeneca and Minhai Biological resources, technology and management experience in the strong combination; AstraZeneca and Minhai Biological strategic cooperation will focus on the vaccine field in the long term, relying on the domestic drug and vaccine research and development and regulatory resources are most concentrated in the Daxing, Beijing, the three parties will work together to explore the innovation of vaccine product pipeline in China, localization of production, clinical research, registration and registration of vaccine products. The three parties will work together to explore potential opportunities for localized production, clinical research, registration and approval and commercialization of innovative vaccine products pipeline in China, accelerate the localized application of vaccine products in China, help vaccine-related industries to further gather and develop, and promote the construction of China's health ecosystem and innovative development of the healthcare industry.

Daxing District, as the main position for the development of Beijing's biomedical industry, has gathered 12 national institutes and testing organizations, such as the China National Institute for Food and Drug Control and the China Veterinary Drug Inspection Institute, forming an industrial ecosystem with key industrial elements such as human resources, land and space, professional platforms, finance, and public services, which covers the following areas: "drug discovery - product development - animal experimentation - clinical research - drug discovery - product development and commercialization". -The industrial ecosystem covers the industrial chain of "drug discovery - product development - animal experiment - clinical research - registration and listing - product sales".

https://mp.weixin.qq.com/s?__biz=MzI2NzE3NDYxNA==&mid=2649719076&idx=1&sn=977f7fab441130d5104cbee36385c4f3&chksm=f299f69dc5ee7f8b66596513a1d77c787e8336621344f8da500f181cf08b5769d3a68003f71f&mpshare=1&scene=1&srcid=0328XS3nkHazmceii12J3Og2&sharer_shareinfo=4560d512eab3cceccfcb2a7e21e9e98b&sharer_shareinfo_first=4560d512eab3cceccfcb2a7e21e9e98b#rd